ASCO 2018 | IDH1 inhibitor ivosidenib for the treatment of relapsed/ refractory AML
Daniel Pollyea
• 1 Jun 2018
A Phase I trial (NCT02074839) investigating the IDH1 inhibitor ivosidenib has demonstrated encouraging results in relapsed/refractory acute myeloid leukemia (AML). In this interview, held at the American Society of Oncology (ASCO) 2018 Annual Meeting, in Chicago, IL, Daniel Pollyea, MD, MS, of the University of Colorado School of Medicine, Denver, CO, shares details of the results from this trial, with impressive overall response and complete remission rates, as well as excellent median overall survival rate for those who achieved remission. Prof. Pollyea explains the next steps for this drug, including further studies looking at combination therapies and different settings.
